2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1570 Prognostic value of clonal hematopoiesis-related genes in adult patients with precursor B cell acute lymphoblastic leukemia

Zihan Ding, Ziyang Zhou2, Chenying Li, PhD3, Jie Jin, MD4
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
Background
The long-term prognosis of adult B-cell acute lymphoblastic leukemia (B-ALL) remains poor, and the prognostic role of clonal hematopoiesis (CH)-related genes in B-ALL has not been fully delineated. This study aimed to systematically characterize the mutational landscape of CH-related genes in adult B-ALL and explore their prognostic significance and therapeutic implications.
Methods
A total of 594 patients with B-ALL admitted to the First Affiliated Hospital of Zhejiang University School of Medicine from January 2020 to December 2025 were retrospectively enrolled. Age-associated genes with significantly higher mutation frequency in elderly patients were filtered from canonical CH driver genes (ASXL1, CALR, DNMT3A, IDH1, IDH2, JAK2, MPL, PPM1D, SF3B1, SRSF2, TET2, TP53, U2AF1 and ZRSR2) using next-generation sequencing data with a 200-gene panel from this cohort. The Kruskal-Wallis rank sum test, Kaplan-Meier method, and Cox proportional hazards regression model were applied to analyze their associations with clinical features and survival outcomes.
Results
The median age of the cohort was 46 years, with a median follow-up of 21 months. Overall, 239/594 (40%) patients were BCR:ABL1-positive and 355/594 (60%) were BCR:ABL1-negative.
Four age-associated CH genes were identified: TP53, TET2, DNMT3A, and IDH1. In the full cohort, TP53 mutations were detected in 65 patients (11%), TET2 in 46 (8%), DNMT3A in 11 (2%), and IDH1 in 16 (3%). All patients were stratified hierarchically according to the priority order of TP53, TET2, DNMT3A, and IDH1 mutations, yielding final subgroups of 65, 37, 11, and 11 patients, respectively; 223 patients without any of the aforementioned variants constituted the wild-type (WT) cohort. Compared with the WT cohort, TP53-mutated patients were predominantly male (p = 0.008); IDH1-mutated patients were older (p = 0.007); patients with TP53 (p < 0.001) or DNMT3A (p = 0.011) mutations had lower bone marrow blast percentages; patients with TP53 (p = 0.028), DNMT3A (p = 0.024) or IDH1 (p = 0.006) mutations had lower white blood cell counts. Among them, TP53 mutations showed a strong correlation with low-hypodiploid/near-triploidy karyotype (p = 0.001).
Complete remission (CR) rates did not differ significantly between the WT group and patients with TP53 (79.5% vs. 80.6%, p = 0.963), TET2 (79.5% vs. 82.9%, p = 0.794), or IDH1 (79.5% vs. 72.7%, p = 0.865) mutations. In contrast, patients with DNMT3A had a lower CR rate compared with WT patients (40.0% vs. 79.5%, p = 0.009).
Survival analysis revealed that patients harboring TP53 or TET2 mutations had significantly inferior overall survival (OS) compared with WT patients (3-year OS of TP53-mutated patients: 62.04% vs. 81.59%, p < 0.001; 3-year OS of TET2-mutated patients: 65.25% vs. 81.59%, p = 0.010). No significant survival difference was observed for patients with DNMT3A or IDH1 mutations relative to WT patients.
In multivariate analysis of the full cohort, BCR::ABL1 positivity was an independent protective factor for OS (HR = 0.438, 95% CI: 0.277- 0.691 ,p < 0.001). Among BCR::ABL1-negative patients, TP53 mutations (HR = 1.958, 95% CI: 1.142- 3.356, p = 0.015) and TET2 mutations (HR = 2.609, 95% CI: 1.278- 5.328, p = 0.008) remained independent adverse prognostic factors for OS.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) conferred significant survival benefits across both mutation subgroups. In BCR::ABL1-negative patients with TP53 mutations, those who underwent allo-HSCT in CR1 had significantly higher 3-year event-free survival (EFS) (67.54% vs. 33.85%, p = 0.005) and OS (71.09% vs. 52.70%, p = 0.046) than those receiving non-transplant therapy. Consistently, among BCR::ABL1-negative patients with TET2 mutations, those who proceeded to allo-HSCT in CR1 had significantly higher 3-year EFS (64.17% vs. 22.22%, p = 0.041) and OS (72.19% vs. 17.78%, p = 0.015) than the non-transplantation group.
Conclusion
TP53 and TET2 mutations serve as independent prognostic biomarkers for BCR::ABL1-negative adult B-ALL. Allo-HSCT in CR1 is warranted in BCR::ABL1-negative patients harboring these high-risk mutations.
Chenying Li, PhD: No relevant conflicts of interest to declare.